DMG patient recruitment firm TrialWire has been selected to recruit patients for a new Pyoderma gangrenosum (PG) study in Australia and New Zealand.
The program leverages the latest in social media and online tools to reach and inform potential patients about the study. The highly targetted methodology called 3PR ensures study information is seen by people who are potentially most eligible and directs them through an advanced communications channel to their nearest participating clinic.
TrialWire is the leading patient recruitment firm for clinical trials in the Australian, New Zealand and Asa region and increasingly the USA and Canada.
